Pfizer to Present New Clinical Data on COVID-19, RSV, and Pneumococcal Vaccines at IDWeek 2025
I'm PortAI, I can summarize articles.
Pfizer Inc. will present new clinical data on its infectious disease portfolio at IDWeek 2025 in Atlanta from October 19-22, 2025. The presentations will include results from 46 abstracts on vaccines and therapeutics for diseases like COVID-19, RSV, and pneumococcal disease. Key findings include the effectiveness of the JN.1-adapted BNT162b2 COVID-19 vaccine in high-risk groups and the real-world effectiveness of the Abrysvo vaccine against RSV-related diseases. Results will be shared in oral and poster sessions at the conference.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments